Clearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) shot up 0.3% on Monday . The company traded as high as $0.84 and last traded at $0.82. 116,706 shares traded hands during trading, a decline of 68% from the average session volume of 360,639 shares. The stock had previously closed at $0.81.
Wall Street Analysts Forecast Growth
CLSD has been the topic of a number of recent research reports. Chardan Capital restated a "buy" rating and set a $6.00 price objective on shares of Clearside Biomedical in a research note on Friday, March 28th. HC Wainwright lowered their price objective on Clearside Biomedical from $6.00 to $5.00 and set a "buy" rating on the stock in a research note on Friday, May 23rd. Needham & Company LLC lowered their price objective on Clearside Biomedical from $4.00 to $3.00 and set a "buy" rating on the stock in a research note on Thursday, May 15th. JMP Securities restated a "market outperform" rating and set a $5.00 price objective on shares of Clearside Biomedical in a research note on Friday, May 16th. Finally, Wall Street Zen upgraded Clearside Biomedical from a "sell" rating to a "hold" rating in a research note on Saturday, May 17th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Clearside Biomedical has a consensus rating of "Moderate Buy" and an average price target of $4.75.
Check Out Our Latest Research Report on CLSD
Clearside Biomedical Trading Down 0.5%
The company has a market cap of $68.04 million, a P/E ratio of -2.14 and a beta of 2.05. The company has a 50 day moving average price of $0.82 and a 200-day moving average price of $0.89.
Clearside Biomedical (NASDAQ:CLSD - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.01. The firm had revenue of $2.33 million for the quarter, compared to analyst estimates of $0.20 million. Equities analysts expect that Clearside Biomedical, Inc. will post -0.48 earnings per share for the current year.
Institutional Investors Weigh In On Clearside Biomedical
Several hedge funds have recently modified their holdings of the company. Investor s Fiduciary Advisor Network LLC bought a new stake in shares of Clearside Biomedical in the 4th quarter valued at about $32,000. Northern Trust Corp raised its stake in Clearside Biomedical by 24.0% during the 4th quarter. Northern Trust Corp now owns 165,499 shares of the company's stock worth $157,000 after buying an additional 32,048 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Clearside Biomedical by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 764,058 shares of the company's stock worth $726,000 after purchasing an additional 32,672 shares in the last quarter. Institutional investors and hedge funds own 18.75% of the company's stock.
Clearside Biomedical Company Profile
(
Get Free Report)
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Featured Stories
Before you consider Clearside Biomedical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clearside Biomedical wasn't on the list.
While Clearside Biomedical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.